Neuropsychiatric Disease and Treatment, 2012 Zhenxin Zhang,1 Lu Yu,2 Maren Gaudig,3 Barbara Schäuble,4 Ute Richarz51Department of Neurology of Peking Union Medical College Hospital, 2Xi’an Janssen Pharmaceutical Ltd, Beijing, China; 3Health Economics and Reimbursement, Janssen ...
Zhang Z +4 more
doaj
Dementia and Geriatric Cognitive Disorders Extra, 2014 Aims: To elucidate the efficacy of galantamine on cognition and behavioral and psychological symptoms of dementia (BPSD) in outpatients with mild cognitive impairment (MCI) and Alzheimer's disease (AD) who have switched from donepezil to galantamine ...
Shoichi Sasaki, Yoshiharu Horie
doaj +1 more source
The Role of Natural Products in Pharmacotherapy of Alzheimer’s Disease [PDF]
, 2003 Alzheimer’s disease is characterized by forgetfulness, disturbance in memory and loss of mental abilities. The final outcome of the disease is loss of personality and intellectual functions.
Singh, Amrit Pal
core +1 more source
ABBV‐552 in patients with mild Alzheimer's disease: a randomized phase IIb trial
Alzheimer's &Dementia, Volume 21, Issue 12, December 2025.Abstract INTRODUCTION This proof‐of‐concept, dose‐finding phase IIb trial evaluated treatment with ABBV‐552 compared with placebo in participants with clinically diagnosed mild Alzheimer's disease (AD). METHODS Participants aged 50 to 90 years with a Mini‐Mental State Examination score of 20 to 26 and a global Clinical Dementia Rating score of 0.5 to 1.
Shau Yu Lynch +6 more
wiley +1 more source
Evaluation of medication treatment for Alzheimer's disease on clinical evidence [PDF]
, 2014 Objective To formulate the best treatment plan for Alzheimer's disease patients by evaluating the therapeutic efficacy and side effect of various evidence-based programs.
Ling LIU +3 more
core +2 more sources
CSF Cholinergic Index, a New Biomeasure of Treatment Effect in Patients With Alzheimer’s Disease
Frontiers in Molecular Neuroscience, 2019 Alzheimer’s disease (AD) is a progressive disease with early degeneration of the central cholinergic neurons. Currently, three of four AD drugs act by inhibiting the acetylcholine (ACh) degrading enzyme, acetylcholinesterase (AChE).
Azadeh Karami +8 more
doaj +1 more source
Perifériás markerek jelentősége Alzheimer-kór diagnózisában és terápiájában = Peripheral markers in the diagnosis and the therapy of Alzheimer`s disease [PDF]
, 2006 A legjelentősebb neurokémiai abnormalitás az Alzheimer-kórban (AK) a központi idegrendszer kolinerg rendszerének csökkent működése, de feltehetőleg a perifériás szövetek is érintettek lehetnek.
Kálmán, János, Rakonczay, Zoltán
core
Nicotinic receptor agonists as neuroprotective/neurotrophic drugs. Progress in molecular mechanisms [PDF]
, 2006 In the present work we reviewed recent advances concerning neuroprotective/neurotrophic effects of acute or chronic nicotine exposure, and the signalling pathways mediating these effects, including mechanisms implicated in nicotine addiction and nAChR ...
BELLUARDO, Natale +2 more
core +2 more sources
Synergistic Effects of Galantamine and Memantine in Attenuating Scopolamine-Induced Amnesia in Mice
Journal of Pharmacological Sciences, 2012 We investigated a possible drug efficacy enhancement obtained by combining inactive doses of galantamine and memantine in the scopolamine-induced amnesia model in mice.
Perrine Busquet +5 more
doaj +1 more source
ASS234, as a new Multi-Target Directed propargylamine for Alzheimer’s disease therapy [PDF]
, 2016 MU and JMC thank MINECO (Spain) for support (Grant SAF2012-33304; SAF2015-65586-R). RRR, MU, GE and JMC thank EU (COST Action 1103) for support.The complex nature of Alzheimer’s disease (AD) has prompted the design of Multi-Target-Directed Ligands (MTDL)
Bolea, Irene +8 more
core +4 more sources